Lilly to lift lid on data for prize ARMO I-O asset at ESMO 2018

At the upcoming congress of the European Society for Medical Oncology (ESMO), Eli Lilly (NYSE: LLY) will present a range of new data, including on the investigational compound pegilodecakin.

Lilly picked up pegilodecakin through its $1.6 billion all-cash acquisition of California’s ARMO BioSciences earlier this year, part of a strategic move to make waves in the immuno-oncology space.

Pegilodecakin is a PEGylated interleukin (IL)-10 which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.